Antibody Discovery

An integrated suite of advanced tools and workflows to accelerate antibody discovery, engineering and validation for biopharma, translational research and diagnostic development. Through our global technology partners, we support every stage of the discovery pipeline—from target identification to lead-candidate selection.

Our capabilities enable:

• Target and antigen discovery using high-resolution genomics, transcriptomics and proteomics workflows

• Monoclonal antibody generation through hybridoma, phage display and recombinant antibody production platforms

• High-throughput screening and characterization, including affinity, specificity, neutralization, and epitope profiling

• Antibody humanization, optimization and engineering for improved efficacy, stability and manufacturability

• Biomarker and immunological signature analysis to identify therapeutic targets and validate immune-related pathways

• Sequence-based antibody discovery combining NGS-enabled repertoire sequencing with advanced bioinformatics

By integrating powerful tools across sequencing, analytical chemistry, cell biology and protein engineering, Scientia Link enables researchers and biopharma teams in the region to accelerate discovery timelines, improve hit-to-lead efficiency, and bring forward high-value antibody candidates with greater precision.